Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q2 2025 earnings on Nov 12, 2024. The consensus estimate for Q2 2025 ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

The S&P 500 Index ($SPX) (SPY) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.69%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Strive Enterprises, a financial services company co-founded by former Republican presidential candidate Vivek Ramaswamy, has announced plans to move its headquarters to Dallas.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the Roivant Sciences stock. Roivant Sciences Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback Roivant (Nasdaq ...

Roivant Sciences, led by biotech entrepreneur Vivek Ramaswamy, has signed a development and licensing agreement with Poxel for the development of a potential oral type 2 oral diabetes drug ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Vivek Ramaswamy (American entrepreneur who founded Roivant Sciences) will also be very influential and will surely support ...